Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement effective June 2026 after a 12-year tenure. Julie Kim, President of Takeda's U.

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. “There's an evolution of our economic model that starts with [the] IRA (Inflation ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s current president, CEO and ...

Takeda could acquire next-generation immunotherapies as it seeks to broaden its offering in the hyper-competitive field of cancer treatment. The Japanese pharma has been building a presence in ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

Bone-chilling temperatures couldn’t keep the crowds away from Takeda’s Kendall Square campus on Tuesday to celebrate a milestone for the Japanese drugmaker’s new R&D tower. More than 250 ...